Phathom Pharmaceuticals (PHAT) Stock: Buy, Sell, or Hold?
PHAT - Phathom Pharmaceuticals, Inc. Common Stock
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 1, 2026 at $6.92 · last confirmed Oct 1, 2026
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
Interactive Price Chart (1 Month)
Loading historical data...
📊 HOLD: PHAT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.6x Exit PE.
In-depth Analysis How we analyze
Technical Outlook: Technically, PHAT is in a strong downtrend. The price is currently testing key support at $6.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PHAT scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $20.45 (+195.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Protect Your Profits
Holding PHAT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 195.6% below Wall St target ($20.45)
- CAUTION: Bottoming setup, but lagging the sector by 38% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-5.2%) - monitor closely
Trading Range Analysis
Support & Resistance Levels
Fundamental Context
Data refreshes hourly during market hours. Next update: 9:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Is PHAT showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
